RxDoctor Payments Data

Donald Kosiak, MD

Family Medicine · Bismarck, NDNPI 1629162706

Payments from drug & device makers

$503in general payments, 2019–2025

Across 23 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$175
  • Acadia Pharmaceuticals Inc$124
  • Johnson & Johnson$33
  • Novartis$25
  • E.r. Squibb & Sons, L.L.C.$21
  • Novo Nordisk$20
  • plus $106 from 6 others

What the payments were for

  • Food & beverage$40881%
  • Education$9519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$503 in reported general payments places this provider in the 70th percentile of 337 family medicine providers in North Dakota.

See all family medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$183,906
Medicare patients
591
Services billed
1,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban508$158,804
Austedo XrDeutetrabenazine18$123,958
XareltoRivaroxaban182$46,681
MounjaroTirzepatide23$26,938
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$25,404
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc232$23,987
MyrbetriqMirabegron115$21,354
AbrysvoRsv Vacc, Pref A And Pref B/Pf60$19,185
XifaxanRifaximin11$17,809
JardianceEmpagliflozin71$17,021
JanuviaSitagliptin Phosphate39$13,852
OzempicSemaglutide13$13,068
Potassium Chloride546$10,201
TresibaInsulin Degludec26$10,013
Budesonide88$9,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$33$46,681182 claims
Novo NordiskOzempic, Tresiba, Fiasp$20$27,71754 claims
Lilly USA, LLCMounjaro$14$26,93823 claims
Boehringer IngelheimJardiance, Spiriva Respimat$18$23,09682 claims
Astellas Pharma US IncMyrbetriq$175$21,354115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$6,89428 claims
AbbVieLinzess$19$6,80212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 337 family medicine providers in North Dakota.

Other family medicine in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →